Perrigo News

Perrigo Co. announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for butoconazole nitrate 2% vaginal cream.

Joseph C. Papa, chairman, president and chief executive officer of the store-brand pharmaceuticals maker, is scheduled to present at the Jefferies Global Healthcare Conference on the morning of June 4 in New York City.

ALLEGAN, Mich., May 22, 2012 /PRNewswire/ -- Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for butoconazole nitrate 2% vaginal cream, the generic equivalent of Gynazole 1 . Perrigo was the first applicant to submit a substantially complete ANDA ... (more)

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia /PRNewswire/ -- Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ... (more)

ALLEGAN, Mich., May 18, 2012 /PRNewswire/ -- Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Lansoprazole capsules .

Perrigo has received final FDA approval for its abbreviated new drug application for Lansoprazole capsules for the treatment of frequent heartburn.

ALLEGAN, Mich., May 15, 2012 /PRNewswire/ -- Perrigo Company today announced that Perrigo Executive Vice President and Chief Financial Officer, Judy L. Brown, will present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 15, at 10:00 AM in Las Vegas, NV.

Perrigo opened at 99.91 on Tuesday. Perrigo has a 52-week low of $75.89 and a 52-week high of $108.60. The company has a market cap of $9.333 billion and a price-to-earnings ratio of 25.29. Perrigo last posted its quarterly earnings results on Tuesday, May 8th.

"The quarter was mixed with concerns linked to weak EU result, lack of guidance update and a combination of the two.

Shares of Perrigo traded down 0.63% during mid-day trading on Wednesday, hitting $99.37. Perrigo has a one year low of $75.89 and a one year high of $108.60. The company has a market cap of $9.272 billion and a P/E ratio of 27.23. Perrigo last announced its earnings results on Tuesday, May 8th.

Stock in Tesla Motors, the electric-car company led by Elon Musk, fell to the lowest price in more than three months after Toyota said its RAV4 SUV with batteries and motor from Tesla costs twice as much as a gasoline version.

PRGO ) third quarter fiscal 2012 adjusted earnings of $1.41 handsomely beat the Zacks Consensus Estimate of $1.21 per share.

GTx, Inc. : GTx announced that the FDA removed its Full Clinical Hold on the company's Investigational New Drug application for Capesaris following the review by the FDA of the Company's complete response and its new Phase II clinical protocol.

ALLEGAN, Mich. &#8212 Perrigo Co., which makes store brand, over-the-counter drugs and infant formulas, said Tuesday that its fiscal third-quarter profit rose from a year ago as new product launches boosted sales.

Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 10:29 a.m. in New York.

Taro Pharma And Perrigo : Both the companies are public. Shares of both the companies trade in reputed US exchanges.

Perrigo Co. will release financial results for the third quarter of its 2012 fiscal year at 8 a.m. on Tuesday, May 8. Joseph C. Papa, chairman, president and chief executive officer of the store brand products maker, will host a conference call with financial analysts and others at 10 a.m. the same day.

Ken Moench has been promoted as QA Label Specification Reviewer for the company's Quality Assurance team.